Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Tuesday, August 29, 2017 11:19:14 AM
- Alzheimer’s is America’s most expensive disease, with a new diagnosis every 66 seconds
- IGC’s unique use of marijuana extracts in combination therapy for potential Alzheimer’s breakthrough shows promise
- Low market cap could make IGC a big winner for early investors
Alzheimer’s disease is one of the greatest medical, ethical, and financial challenges facing society today. Currently, more than 5.3 million Americans and their families have to deal with Alzheimer’s disease, and projections suggest that number will nearly triple to 14 million Americans by 2050. Globally, the figures are even more staggering, with about 47 million people worldwide currently diagnosed and projections at 132 million in less than three decades. Right now, someone in America develops Alzheimer’s every 66 seconds, and soon, this deadly diagnosis is expected to occur every 33 seconds.
Alzheimer’s is already the country’s most expensive disease. In 2016 U.S. costs totaled $236 billion and global costs exceeded $600 billion. These figures will skyrocket unless scientists develop new approaches to prevent or cure this insidious disease. Given the magnitude of the problem, pharmaceutical companies are scrambling to find ways to mitigate the disease’s devastation.
With so much on the line, it’s no wonder that Wall Street has already started to place bets on who might be a winner in this race. In this vein, Goldman Sachs recently highlighted Biogen (NASDAQ: BIIB) and its lead pipeline Alzheimer’s drug as one of the first to possibly prevent or slow the progression of the disease (http://nnw.fm/H4Py2). Goldman pegged potential drug sales at over $12 billion and targeted the $60 billion market cap stock at a 17 percent premium, if successful. However, everyone knows there are no guaranteed winners in this race. A broad spectrum of options must be considered if investors want to participate in the enormous upside potential of an effective Alzheimer’s treatment.
One compelling candidate with a promising patent pending Alzheimer’s treatment protocol and ridiculously low market valuation is India Globalization Capital (NYSE MKT: IGC). IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics include treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease.
IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.
IGC plans to enter clinical trials this year on its potential cannabis-based blockbuster treatment for Alzheimer’s, as well as on the company’s primary pipeline of other major therapeutics that address large market maladies. Any one of these trials could provide breakthrough treatments for previously untreatable disease. With a market capitalization currently around $10 million, IGC is one very interesting bet investors may want to place in this race for an effective Alzheimer’s treatment. Any positive results from the clinical trials could easily catapult valuation and make IGC a big winner for early investors.
For more information, please visit www.IGCInc.us
Recent IGC News
- IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment • Business Wire • 09/18/2024 12:00:00 PM
- IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease • Business Wire • 09/04/2024 12:00:00 PM
- IGC Announces Results of its 2024 Annual Stockholders Meeting • Business Wire • 08/26/2024 11:00:00 PM
- IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease • Business Wire • 08/22/2024 01:00:00 PM
- IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist • Business Wire • 08/20/2024 12:00:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/14/2024 08:23:18 PM
- IGC Pharma Reports First Quarter Fiscal 2025 Results • Business Wire • 08/09/2024 01:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 06:38:52 PM
- IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target • Business Wire • 07/18/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/09/2024 06:17:37 PM
- Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile • Business Wire • 07/09/2024 01:10:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/08/2024 08:07:05 PM
- IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease • Business Wire • 06/25/2024 01:00:00 PM
- IGC Reports Financial Results for Fiscal Year Ended March 31, 2024 • Business Wire • 06/24/2024 11:30:00 PM
- IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets • Business Wire • 06/18/2024 01:00:00 PM
- IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol • Business Wire • 06/10/2024 01:00:00 PM
- IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1 • Business Wire • 05/28/2024 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/22/2024 01:20:27 AM
- IGC Pharma to Attend BIO International Convention 2024 • Business Wire • 05/21/2024 06:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 01:54:41 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 01:53:35 AM
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two • Business Wire • 04/16/2024 11:00:00 AM
- IGC Pharma Adds Advisor in Artificial Intelligence • Business Wire • 04/09/2024 01:00:00 PM
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock • Business Wire • 03/26/2024 07:00:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM